Glioblastoma is a leading cause of cancer-related death in pediatric patients.
There are no approved therapies for Pediatric Brain tumors.
Current therapies are ineffective and have devastating side effects.
Treovir’s G207 Therapy demonstrated improved survival in a Phase 1 study without any serious side effects.
A TREOVIR
Success Story
University of Alabama at Birmingham and Children’s of Alabama
Nick Tasoglou came to UAB and Children’s of Alabama after being diagnosed with a brain tumor. 5 months after G207 treatment, scans showed holes forming in the tumor at the G207 injection sites. More than 4 years after a single G207 treatment, with no other therapies, Nick has shown a strong response.
Together We Can Strive To
Our Common Goal
Treovir will launch a Phase 2 clinical study for G207 in 2021 that is designed to seek
market approval to treat pediatric patients with recurrent pediatric gliomblastoma.
TREOVIR NEWS
Check Out What's New
Treovir Announces Positive Results of Phase 1 Study of G207 in Pediatric Patients with Recurrent High-Grade Glioma
New England Journal of Medicine published the Phase 1 trial data on April 10,...
Treovir Awarded Phase 2 SBIR Grant to Support G207 Clinical Development
Treovir announces that it has been awarded a $2 million Phase 2 SBIR grant...
G207 Fast Track Designation
Treovir announces today that G207 has been granted Fast Track Designation by the US...
Treovir Announces G207 Acquisition
Treovir announces today that it has executed an Asset Acquisition Agreement with Aettis, Inc....
G207 Orphan Designation
Treovir announces that G207 has been awarded Orphan Drug designation by the US FDA...
Treovir collaborates with a number of institutions for the development of G207.
